Atai Life Sciences N.V.
ATAI
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a choā¦ read more
Healthcare
Biotechnology
2 years
USD
33
/100
Price
per share adjusted in USD$1.52
Price0.00%
$0.00
5Y
Price
Market Cap
$303.688m
Small
Price/Earnings
-6.9x
-
3y Avg-
5y AvgDividends
Ex-Dividend: -0.00%
Yield$0.00
Dividend0.00%
Forward Dividend Growth
-
-
3y CAGR-
5y CAGRPayout
0.00%
-
Payout 3y-
Payout 5yYield
BenchmarkDividends
No items found.
Financials Overview
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$378k
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$58.073m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$0.37
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$168.533m
$215.778m
Assets$47.245m
Liabilities$17.583m
DebtDebt to Assets
8.2%
-0.2x
Debt to EBITDAFree Cash Flow
-$78.195m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metricsNo items found.
Press Releases